Biotech

All Articles

iTeos- GSK's TIGIT star presents relevant improvement

.After introducing a phase 3 launch based on positive midstage results, iTeos and GSK are eventually...

More joint FDA can increase unusual disease R&ampD: document

.The FDA must be actually more available and also joint to release a rise in approvals of rare condi...

Zenas, MBX, Bicara head to Nasdaq in scorching day for biotech IPOs

.It is actually an unusually active Friday for biotech IPOs, along with Zenas BioPharma, MBX and als...

Atea's COVID antiviral neglects to stop hospitalizations in period 3

.Atea Pharmaceuticals' antiviral has actually neglected one more COVID-19 trial, but the biotech sti...

Neurocrine's offer to save schizophrenia possibility fails

.Neurocrine Biosciences' schizophrenia plan pivot has actually stopped working. The biotech was inca...

Sanofi pays for $110M upfront for late-stage radioligand therapy

.Sanofi has actually created a late access to the radioligand gathering, paying for 100 million euro...

F 2G brings up $100M for second effort to acquire new antifungal to market

.After F2G's first effort to receive a new course of antifungal to market was hindered due to the FD...

Moderna targets $1.1 B in R&ampD costs slices, drops 5 programs among profits tensions

.Moderna has actually pledged to reduce R&ampD investing by $1.1 billion through 2027. The decision ...

Sanofi's $80M bet on Pivot dystrophy medication finishes in phase 3 go belly up

.Only four months after Sanofi wager $80 million in ahead of time money on Key Therapeutics' losmapi...

Oncternal assets drains 60% surrounded by cutbacks, test firings

.Cancer company Oncternal Rehabs is folding all its own scientific tests as well as giving up staff,...